Other content tagged: Retinopathy of Prematurity
One- and two-year follow-up outcomes of the CARE-ROP study
The CARE-ROP study identified ranibizumab as an effective treatment to control acute retinopathy of prematurity (ROP), an eye disease that affects preterm babies. For 16 preterm children entering the follow-up period, their ophthalmologic- and neurodevelopment was assessed at the one-year and two-year visits post-baseline. The patients’ outcomes of ranibizumab usage are very reassuring regarding long-term safety. Yet, late reactivation of ROP can represent a challenge and calls for regular follow-ups. Retinopathy of prematurity is…
Read more
Retinopathy Of Prematurity: Keep up the screening process, even in difficult times – An interview with Professor Doctor Andreas Stahl
In times of self-isolation during the COVID-19 pandemic, concerned parents are often uncertain whether they should take their babies to screening and follow-up appointments. Retinopathy of Prematurity is an eye disease that affects mainly very preterm born babies and requires a close screening. Professor Andreas Stahl, Director and Chair of Ophthalmology, University Medicine Greifswald clarifies why screening should not be postponed. Professor Stahl, is there anything one should consider regarding COVID-19 when it comes to treatment of ROP? The key…
Read more
Retinopathy of prematurity – not only an acute condition? An interview with Professor Armin Wolf
Interview with Professor Armin Wolf, Deputy Hospital Director, Eye Hospital, Ludwig-Maximilians-University Munich Retinopathy of Prematurity (ROP) is a condition that is found in the eyes of very preterm born babies. It is characterised by changes in the developing blood vessels of the retina (the light-sensitive layer in the back of the eye that sends visual signals to the brain). If detected timely, it can usually be treated and a blindness can be prevented. Still, it is a condition of the…
Read more
